Abbott Becomes CRM Player Overnight By Completing St. Jude Deal
Abbott Laboratories has finalized its $25b takeover of St. Jude Medical, first announced in April, making Abbott a major player in almost every corner of the $30bn cardiovascular device market.
You may also be interested in...
Deepak Nath will take over as Smith & Nephew’s new CEO on 1 April, joining the orthopedics and wound care company after four years as president of Siemens Healthineers’ diagnostics business. Smith & Nephew’s current CEO Roland Diggelmann is stepping down by mutual agreement.
US regulators have notified the public about a recall of certain Abbott Ellipse implantable cardioverter defibrillators that are prone to electrical shorting due a manufacturing flaw. While the number of devices so far in the US is very small, the recall highlights continued issues with the ICDs since Abbott acquired them from St. Jude almost three years ago.
The company's device business chief is expanding his portfolio as Abbott's new president and chief operating officer, leading to some speculation that he is being positioned to be the next CEO.